中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2012, Vol. 47 Issue (10) :749-753    DOI:
����ҩѧר�� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
����������ҩ���ݱ����ƶȼ���Զ�ͯ��ҩ��ȫ��Ӱ�����
����ϣ�����ģ��׸���
�й�ҩ�ƴ�ѧҽҩ֪ʶ��Ȩ�о������Ͼ� 211198

Download: PDF (1131KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� Ϊ�ҹ����ƶ�����ҩ��������ṩ�ο������� ���ð�����������������������ҩ���ݱ������߶Զ�ͯ��ҩ��ȫ��Ӱ�졣�������� ����������ҩ���ݱ���������һ���̶��ϼ����˶�ͯ�ٴ��о��Ŀ�չ������˶�ͯ��ҩ�İ�ȫ�ԣ��ҹ����Խ�������ijɹ����飬����������ҩ���ݱ����ƶȣ�����ҹ���ͯ����ˮƽ��
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
����ϣ
����
�׸���
�ؼ����� ������ҩ   ���ݱ���   ��ͯ��ҩ��ȫ     
Abstract��
Keywords��   
�ո�����: 2012-02-03;
���߼��: ����ϣ���У������ڣ�˶ʿ����ʦ �о�����ҽҩ�����뷨�棬ҽҩ֪ʶ��Ȩ Tel��13605152326 E-mail��dingjinxi@yahoo.com.cn
���ñ���:   
����ϣ, ����, �׸��� .����������ҩ���ݱ����ƶȼ���Զ�ͯ��ҩ��ȫ��Ӱ�����[J]  �й�ҩѧ��־, 2012,V47(10): 749-753
DING Jin-Xi, DENG Mei, BAI Geng-Liang .[J]  Chinese Pharmaceutical Journal, 2012,V47(10): 749-753
��
[1] LI Z P. Importance of pediatric drug clinical trial [J]. J Pediatr Pharm(����ҩѧ��־)��2009��15(4)��4-5.
[2] LUO C��LI Y��YANG L. Pediatric drug policies in the USA and Its Illumination for hina[J]. J China Pharm(�й�ҩ��)��2009��20(28)��2168-2170.
[3] FDA. Implementation of the Pediatric Exclusivity Provisions [EB/OL]. http�� //www. fda. gov /News Events /Testimony/ucm115220. htm.
[4] FDA. Guidance for Industry-Qualifying for Pediatric Exclusivity Under Section505A of the Federal Food��Drug and Cosmetic Act[EB/OL]. http��//www. fda. gov/cber/gdlns/pedexc. htm.
[5] YANG L��LUO C��CHEN J. Pediatric exclusivity system (��)[J]. Chin J New Drugs(�й���ҩ��־)��2009��18(8)��677-680.
[6] SMITH P B�� BENJAMIN JR D K�� MURPHY M D�� et al. Safety monitoring of drugs receiving pediatric marketing exclusivity[J]. Pediatrics�� 2008��122(3)��628-633.
[7] ALAN M. SHAPIRO M D. Implementation of the Best Pharmaceuticals for Children Act�� the FDA Pediatric Post-Marketing Safety Review Experience [EB/OL]. http��//www. fda. gov/downloads/AboutFDA/CentersOffices/CDER/ucm120016. pdf
[8] ZHANG H F��LI P P��WANG Y��et al. Large sample survey and analysis of the application of the pediatric antimicrobial drug[J]. Chin Pharm J(�й�ҩѧ��־)��2007��42(16)��1268-1270.
[9] LIANG Y P��ZHANG X P��ZHAO Q. Analysis of 181 cases of the use of pediatric lower respiratory tract antibacterial drug survey[J]. Chin Pharm J���й�ҩѧ��־����2009��44(1)��70-72.
[10] XIE J P��WU Y H. The use of pediatric inpatient antimicrobial drug in the hospital[J]. Chin Pharm J (�й�ҩѧ��־)��2006��41(2)��157-158.
[11] FDA. Pediatrics - Safety Reporting[EB/OL]http��//www. fda. gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/ucm123229. htm.
[12] FDA. Pediatric Exclusivity Statistics as of November 30��2011[EB/OL]. http��//www. fda. gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm050006. htm.
[13] FDA. Pediatric Labeling Changes Table throughTuesday�� October 25�� 2011[EB/OL]. http��//www. fda. gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/UCM163159. pdf.
[14] ZHANG L H��WEI P. Analysis and measures of the current situationpediatric of pediatric drug registration in the hospital[J]. Pharm J Chin PLA(��ž�ҩѧѧ��)��2011��27 (2)��178-180.
[15] HOU N��GAO J X��WANG Q. Analysis of the pediatric prescription drugs varietiesin the hospital[J]. Chin Pharm J (�й�ҩѧ��־)��2005��40(13)��1038-1039.
[16] SHEN L��WANG Y L. Analysis on the results of pediatric studies for 153 products under the pediatric exclusivity program in USA[J]. Chin J Pharmacovigilance(�й�ҩ�ᆵ��)��2011(8)��468-473.
Copyright 2010 by �й�ҩѧ��־